Butterfly-Shaped Pigment (Pattern) Dystrophy

Butterfly-shaped pigment dystrophy is a rare, inherited macular condition in which pigment and waste material (mainly lipofuscin) build up in the retinal pigment epithelium (RPE) in a pattern that looks like a butterfly at the center of the retina (the macula). The RPE helps nourish and recycle the light-sensing cells (photoreceptors). When the RPE does not work well, vision can blur or become distorted, usually slowly and often beginning in mid-life or later. On exam and imaging, doctors see a butterfly-like figure at the macula, with areas that are brighter or darker than normal depending on how lipofuscin has accumulated or the RPE has thinned. Orpha+2rarediseases.info.nih.gov+2

Butterfly-shaped pigment dystrophy is a rare, inherited macular condition where pigment under the central retina (the retinal pigment epithelium, RPE) forms a shape that looks like a butterfly. The pigment makes the macula look like it has 3–5 “wings.” Many people have few or no symptoms for years. Some notice blurred central vision, trouble reading, or mild distortion. On eye scans and angiography, doctors see the butterfly pattern clearly. There is no proven medicine that cures the disease, but most people keep fairly stable vision for a long time. A small number develop a complication called choroidal (macular) neovascularization (CNV)—abnormal leaky vessels under the macula—which can reduce vision but can be treated. NCBI+1

BSPD often happens due to changes in genes that help build and maintain the light-sensing part of photoreceptors and their connection to the RPE. A key gene is PRPH2 (also called RDS); other genes can be involved, and variable patterns can occur even within one family. Genetic counseling helps families understand inheritance and testing options. MedlinePlus+2PMC+2

Other names

People and articles may use several names for the same disease. All refer to the same clinical entity when “butterfly” and “pattern dystrophy” are used together:

• Butterfly-shaped pattern dystrophy

• Butterfly-shaped pigment dystrophy of the fovea

• Pattern dystrophy of the RPE—butterfly type
  These names sit within a bigger family called pattern dystrophies—hereditary macular disorders marked by patterned pigment changes at the RPE (other family members include adult-onset foveomacular vitelliform dystrophy, reticular dystrophy, multifocal pattern dystrophy simulating Stargardt disease, and fundus pulverulentus). NCBI+2EyeWiki+2

Types

Strictly speaking, BSPD is itself one “type” of pattern dystrophy. Clinicians still find it useful to label what they see over time or on different imaging tests. In plain English, you might hear these “types/appearances” of BSPD:

1. Classic butterfly pattern at the macula – the typical wing-like figure formed by streaks or spokes of pigment at the fovea, often fairly symmetric in the two eyes. ScienceDirect

2. Butterfly pattern with surrounding depigmentation – the central butterfly is ringed by a paler halo from RPE thinning; this can make edges look sharp on autofluorescence images. ScienceDirect

3. Atrophic (worn-down) stage – over years, some areas lose RPE and photoreceptors, leaving patches of geographic atrophy at the macula with more noticeable central vision symptoms. NCBI

4. Butterfly pattern complicated by choroidal neovascularization (CNV) – rarely, new leaky blood vessels grow under the macula; this can cause sudden blur or distortion and needs prompt attention. NCBI

5. Genetically labeled BSPD – most often linked to PRPH2 (also called RDS) gene variants; rarely other genes (for example, CTNNA1) have been reported with butterfly-like changes. Clinicians sometimes say “PRPH2-related butterfly dystrophy.” PMC+2MedlinePlus+2

Take-home: the “type” a doctor uses usually reflects what your macula looks like now and what the imaging shows, not a different disease.

Causes

Main cause: inherited gene changes that affect RPE–photoreceptor support. Most families with BSPD have a change (variant) in the PRPH2 (RDS) gene, which makes peripherin-2, a protein needed to form and stabilize the outer segments of photoreceptors. Faulty peripherin-2 disrupts the handshake between photoreceptors and RPE, so waste (lipofuscin) piles up in patterns. Rarely, variants in CTNNA1 (alpha-catenin) can create a similar butterfly pattern. The items below explain the full picture patients and clinicians talk about. MedlinePlus+2PMC+2

1. PRPH2 (RDS) gene variants – the best-established genetic cause; usually autosomal dominant, so a parent often carries the variant. PMC+1

2. CTNNA1 gene variants (uncommon) – reported families show butterfly-like macular lesions with this gene too. PMC

3. RPE lipofuscin accumulation – lipofuscin is a wear-and-tear pigment; too much in the RPE is central to the butterfly appearance. Orpha+1

4. Photoreceptor outer-segment instability – peripherin-2 defects destabilize disks, stressing the RPE. MedlinePlus

5. RPE transport and recycling stress – the RPE cannot keep up with daily photoreceptor waste, so deposits appear in patterns. NCBI

6. Age – many people notice symptoms in mid-life or later, likely because damage accumulates over time. rarediseases.info.nih.gov

7. Oxidative stress in the macula – the macula uses lots of oxygen and light; oxidative stress can worsen RPE injury. (Inference consistent with RPE-lipofuscin literature.) ScienceDirect

8. Light exposure over decades – cumulative light may aggravate lipofuscin build-up in vulnerable RPE. (General mechanism discussed in lipofuscin/RPE imaging reviews.) ScienceDirect

9. Modifier genes – people with the same PRPH2 variant can look very different; other genes likely modify severity. PMC

10. Incomplete penetrance/variable expressivity – some carriers have mild or late changes; this family behavior is common. NCBI

11. RPE–Bruch’s membrane changes – structural aging can reveal or magnify pattern lesions. NCBI

12. Metabolic load from photoreceptors – high daily turnover stresses the RPE in the central retina most. MedlinePlus

13. Inflammation (low-grade, secondary) – not a primary cause but can worsen RPE stress in some eyes. (Inference from RPE dysfunction frameworks.) NCBI

14. Microvascular/RPE perfusion imbalance – rarely implicated, but impaired support may hasten atrophy or CNV. NCBI

15. Smoking – generally harmful to macular health; while data are strongest for AMD, clinicians advise avoidance in inherited macular disease too. (Risk-reduction guidance extrapolated.) NCBI

16. Systemic oxidative conditions (e.g., poorly controlled diabetes) – may increase oxidative stress burden on the RPE. (General mechanism; not a primary genetic cause.) NCBI

17. Phototoxic medications (rare, theoretical) – drugs that increase light sensitivity could add stress in vulnerable RPE. (General caution; not a core driver.) NCBI

18. Coexisting retinal disease – other macular disorders can overlay BSPD and accelerate symptoms. NCBI

19. Hormonal/age-related retinal changes – life-course shifts in metabolism may influence expression. (Inference consistent with variable onset.) rarediseases.info.nih.gov

20. Random (stochastic) cellular wear – even with the same mutation, chance cellular events shape how patterns form over decades. (General explanation for variability.) PMC

Symptoms

Not everyone notices problems, and many people keep good central vision for years. When symptoms occur, they usually progress slowly:

1. Blurry central vision—words look fuzzy or less sharp when reading. rarediseases.info.nih.gov

2. Metamorphopsia—straight lines look wavy or bent (an Amsler grid can show this). journalor.com

3. A small gray or dark spot near the center (central scotoma)—you may notice a “smudge” while focusing. NCBI

4. Reduced contrast—light gray on white or low-contrast print becomes hard to see. NCBI

5. Glare sensitivity—bright light makes detail harder to pick out. NCBI

6. Slow dark adaptation—it takes longer for your eyes to adjust in dim rooms. NCBI

7. Color vision changes—subtle colors are harder to tell apart. NCBI

8. Difficulty with fine tasks—threading a needle or tiny fonts becomes tougher. rarediseases.info.nih.gov

9. Reading fatigue—words blur or “swim” after a while. rarediseases.info.nih.gov

10. Photopsias (brief flashes)—some people notice brief flickers. NCBI

11. Mild night vision trouble—especially with small, low-contrast targets. NCBI

12. Uneven vision between eyes—one eye can seem worse than the other. NCBI

13. Difficulty recognizing faces at a distance—fine central detail is reduced. rarediseases.info.nih.gov

14. Sudden new distortion or blur—this is uncommon but can signal CNV and needs urgent evaluation. NCBI

15. Often no symptoms at first—many people are diagnosed from routine eye photos. journal.opted.org

Diagnostic tests

Doctors combine what you say, what they see, and what imaging shows. Here are the common tests, grouped just as you asked.

A) Physical exam & history

1. Detailed history – the doctor asks about age of onset, slow change, family history (because inheritance is often dominant), and sudden changes that might hint at CNV. This guides which tests to do next. NCBI

2. Best-corrected visual acuity (distance and near) – measures how clearly you can see with optimal glasses; this tracks change over time. NCBI

3. Amsler grid at near – a simple grid you view at reading distance; waves, kinks, or missing squares suggest macular disturbance like metamorphopsia. NCBI

4. Dilated fundus exam – the clinician looks at your macula with lenses. In BSPD, the butterfly-like pigment figure lies at the fovea and can be subtle or obvious; both eyes are usually affected. EyeWiki

5. Color vision and contrast testing – standardized plates or contrast charts help quantify color and contrast problems common in macular disease. NCBI

B) “Manual” chair-side functional tests

6. Photostress recovery time – after a brief bright light, how quickly vision returns helps localize macular/RPE dysfunction; longer times fit RPE/photoreceptor stress. NCBI

7. Near reading performance (reading speed/acuity) – quick chair-side checks can document central-vision efficiency changes over time. NCBI

8. Preferential hyperacuity/shape discrimination tests – simple instruments or apps pick up tiny distortion, useful when fundus changes are subtle. NCBI

9. Fixation stability assessment – observing whether the eye can hold steady on a small target; unstable fixation suggests macular disturbance. NCBI

10. Amsler grid with color or low contrast – variations can make subtle metamorphopsia more obvious in BSPD. NCBI

C) Laboratory & pathological/genetic tests

11. Genetic testing for PRPH2 (RDS) – the key confirmatory test in typical families; finding a pathogenic variant clinches the inherited diagnosis and helps counsel relatives. PMC+1

12. Reflex panel including CTNNA1 (select cases) – if PRPH2 is negative or the picture is unusual, panels for rare genes can detect other causes. PMC

13. Cascade testing of relatives – once a family variant is known, testing adult relatives can identify those who should have periodic macular checks. PMC

14. Variant classification by accredited lab – proper classification (pathogenic/likely pathogenic) helps avoid over-calling harmless variants. PMC

15. (Research only) Tissue pathology correlations – historical reports show lipofuscin-rich RPE and photoreceptor changes that match clinical images. This is not a routine clinical test but explains the disease biology. JAMA Network

D) Electrodiagnostic tests

16. Full-field ERG (electroretinogram) – often near normal or mildly reduced in pattern dystrophies because they are macula-predominant; helpful to rule out more widespread retinal disease. NCBI

17. Multifocal ERG – maps macular responses and can show depressed central function matching the butterfly area. NCBI

18. EOG (electro-oculogram) – typically normal or only mildly abnormal in BSPD, which helps distinguish it from Best disease where EOG is often markedly reduced. NCBI

E) Imaging tests

 

19. Color fundus photography – documents the butterfly pattern for baseline and follow-up. journal.opted.org

20. Fundus autofluorescence (FAF) – highlights lipofuscin. In BSPD, FAF shows mixed bright and dark butterfly-shaped signals, helping confirm the diagnosis and track change. EyeWiki+1

21. Optical coherence tomography (OCT) – cross-sectional “slices” show RPE irregularities and ellipsoid-zone changes under the macula; thickness is often preserved until late. MDPI

22. OCT-angiography (OCT-A) – non-dye imaging to screen for abnormal new vessels (CNV) if vision acutely worsens. MDPI

23. Fluorescein angiography (FA) – dye test that can reveal the classic butterfly pattern when photos are subtle and can detect leakage from CNV that needs treatment. EyeWiki

24. Near-infrared reflectance imaging – can outline the pattern and atrophic borders; helpful when FAF is equivocal. MDPI

25. Serial imaging over time – comparing photos, FAF, and OCT from year to year shows whether atrophy is expanding or CNV has appeared. IOVS

Non-pharmacological treatments (therapies & others)

1. Regular dilated eye exams with OCT/FA as needed
   Purpose: Find early changes, catch CNV quickly. Mechanism: OCT visualizes layers; fluorescein angiography shows leakage or blocked fluorescence forming the “butterfly.” Early detection allows timely anti-VEGF if CNV appears. NCBI

2. Amsler grid self-monitoring (weekly)
   Purpose: Notice new distortion/blind spots fast. Mechanism: Self-test of central vision; sudden wavy lines/dark spots can signal CNV and prompt urgent visit. en.octclub.org

3. Low-vision rehabilitation referral (when daily tasks are affected)
   Purpose: Improve reading, mobility, and independence. Mechanism: Prescribes magnifiers, high-contrast strategies, task lighting, and training; it’s a standard of care. American Academy of Ophthalmology+1

4. Task and ambient lighting optimization
   Purpose: Reduce glare, improve contrast. Mechanism: Directional LED lighting and diffusers increase retinal image quality; tinted lenses may help comfort. American Academy of Ophthalmology

5. Electronic magnification & accessibility tools
   Purpose: Easier reading/working. Mechanism: CCTV/handheld video magnifiers, smartphone zoom/voiceover enlarge letters and enhance contrast. American Academy of Ophthalmology

6. Orientation & mobility training (if vision loss progresses)
   Purpose: Safe navigation. Mechanism: Teaches scanning, contrast cues, and route planning to work around central scotomas. American Academy of Ophthalmology

7. Anti-glare, UV-blocking eyewear
   Purpose: Comfort and potential RPE protection. Mechanism: Filters UV/short-wavelength light that increases glare and light scatter, improving function for many. American Academy of Ophthalmology

8. Smoking cessation
   Purpose: Protect retina and overall eye health. Mechanism: Smoking increases oxidative stress and vascular risk; stopping supports retinal health. (Supplements with beta-carotene are avoided in smokers due to lung cancer risk in AREDS data.) nei.nih.gov

9. Cardiometabolic risk control (BP, lipids, sugar)
   Purpose: Support macular perfusion and reduce general eye risk. Mechanism: Good vascular health supports the choroid/RPE; comorbidity control improves outcomes in retinal disease. American Academy of Ophthalmology

10. Genetic counseling ± testing
    Purpose: Clarify inheritance, recurrence risk, and future trial eligibility. Mechanism: Targeted or panel testing of IRD genes (e.g., PRPH2) informs family planning and follow-up. American Academy of Ophthalmology

11. Workplace/school accommodations
    Purpose: Maintain productivity. Mechanism: Accessibility settings, large-print materials, screen readers, and lighting accommodations. Guideline Central

12. Contrast-enhancing strategies
    Purpose: Make text/objects pop. Mechanism: Bold fonts, matte paper, high-contrast themes on devices improve legibility with macular disease. American Academy of Ophthalmology

13. Nutritional pattern emphasizing leafy greens & colorful produce
    Purpose: Support macular pigment/overall eye health. Mechanism: Diet rich in lutein/zeaxanthin provides macular pigments (lutein/zeaxanthin sit in the macula and filter blue light). nei.nih.gov

14. Omega-3–rich diet (fish twice weekly)
    Purpose: General retinal support. Mechanism: DHA/EPA are retinal membrane lipids; while AREDS2 supplements didn’t add benefit, dietary intake is reasonable. nei.nih.gov

15. Avoid unnecessary high-dose vitamin A derivatives
    Purpose: Reduce theoretical risk of lipofuscin stress in certain dystrophies; discuss with clinician. Mechanism: Some IRDs manage retinoid load carefully; individualized advice is needed. American Academy of Ophthalmology

16. Photoprotection after PDT (if performed)
    Purpose: Prevent skin photosensitivity reactions. Mechanism: Strict light avoidance after verteporfin reduces adverse reactions. FDA Access Data

17. Prompt evaluation of new symptoms
    Purpose: Time-sensitive CNV care. Mechanism: Early anti-VEGF improves outcomes in CNV across etiologies. bmjophth.bmj.com

18. Community low-vision resources & training
    Purpose: Ongoing skills and support. Mechanism: Structured programs and courses enhance independence. American Academy of Ophthalmology

19. Fall-prevention home audit
    Purpose: Safety with reduced contrast. Mechanism: Lighting, anti-slip surfaces, high-contrast edges lower fall risk in central vision loss. American Academy of Ophthalmology

20. Stay trial-aware (research registries)
    Purpose: Consider future gene-agnostic or cell-based studies. Mechanism: Registries and foundations post IRD trial updates; PRPH2-specific trials are limited at present. fightingblindness.org

---

Drug treatments

Important: No drug is FDA-approved specifically for BSPD. When CNV occurs, clinicians treat it similarly to other CNV conditions using anti-VEGF or, in selected cases, photodynamic therapy (PDT). The anti-VEGF labels below are from accessdata.fda.gov; indications are typically nAMD/DME/RVO/myopic CNV, so BSPD-CNV use is off-label. Case reports and small series in pattern dystrophies show benefit. Dosing and adverse effects come from FDA labels. PMC+2Europe PMC+2

1. Ranibizumab (Lucentis®) — anti-VEGF-A monoclonal fragment
   Class: VEGF-A inhibitor. Dose/Time: 0.5 mg intravitreal, typically monthly then extend per response. Purpose: Dry down CNV leakage, improve/maintain vision. Mechanism: Neutralizes VEGF-A to stop abnormal vessel growth and leakage. Side effects: Conjunctival hemorrhage, IOP rise, eye pain; rare endophthalmitis/retinal detachment; systemic arterial thromboembolic events are rare. Evidence note: Pattern-dystrophy CNV case reports show vision and anatomy improvement. FDA Access Data+2FDA Access Data+2

2. Aflibercept (Eylea® / Eylea HD®) — VEGF-A/VEGF-B/PlGF trap
   Class: Fusion protein VEGF trap. Dose/Time: 2 mg q4w × 3, then q8w; HD 8 mg has longer intervals per label. Purpose/Mechanism: Binds VEGF-A/-B and PlGF to suppress CNV leakage. Side effects: Conjunctival hemorrhage, cataract, vitreous floaters, IOP increase; rare endophthalmitis/retinal detachment. FDA Access Data+2FDA Access Data+2

3. Brolucizumab (Beovu®) — anti-VEGF-A single-chain antibody fragment
   Class: VEGF-A inhibitor. Dose/Time: Per label for nAMD: q4–12w after loading. Purpose/Mechanism: Potent VEGF-A neutralization allowing longer intervals. Key safety: Label warns about retinal vasculitis/occlusion; careful monitoring required. FDA Access Data+1

4. Faricimab (Vabysmo®) — dual angiopoietin-2/VEGF-A inhibitor
   Class: Bispecific mAb (anti-VEGF-A, anti-Ang-2). Dose/Time: Label permits extended intervals after loading in nAMD/DME. Purpose/Mechanism: Blocks VEGF-A and Ang-2 to reduce leakage and vascular instability. Side effects: Cataract, conjunctival hemorrhage; standard intravitreal risks apply. FDA Access Data+1

5. Verteporfin (Visudyne®) PDT — photosensitizer used with laser light
   Class: Photodynamic drug. Dose/Time: IV verteporfin with 689-nm laser (50 J/cm² over ~83 sec), repeat by leakage status. Purpose/Mechanism: Light-activated drug closes CNV selectively. Key safety: Photosensitivity for ~48 hours; potential back pain during infusion; label limits to certain CNV types. FDA Access Data+1

6. Ranibizumab biosimilars (e.g., Byooviz®) — anti-VEGF-A
   Class/Dose/Mechanism/Effects: Similar to reference ranibizumab; follow label for indications and safety. FDA Access Data

7. Topical antibiotic prophylaxis (peri-injection, clinic-specific practice—not routinely required)
   Class: Fluoroquinolones, etc. Purpose: Some clinics use peri-injection antisepsis strategies; povidone-iodine is standard; routine antibiotics are often avoided. (Practice pattern note rather than BSPD-specific.) American Academy of Ophthalmology

8. Topical IOP-lowering agents (as needed)
   Purpose: Brief IOP spikes after injections can be treated in clinic if needed. Mechanism: Aqueous suppression or outflow boost. (General intravitreal care principle.) FDA Access Data

9. Topical corticosteroids (select, short-term for injection-related inflammation only)
   Purpose: Calm sterile inflammation after injections when present. Mechanism: Anti-inflammatory; not a BSPD treatment. (Clinic practice, patient-specific.) FDA Access Data

10. Cycloplegic/NSAID drops for comfort (case-by-case)
    Purpose: Reduce ciliary spasm or surface discomfort post-procedure. Mechanism: Symptomatic relief; not disease-modifying. American Academy of Ophthalmology

11. Artificial tears/lubricants
    Purpose: Comfort during frequent visits/injections. Mechanism: Surface stabilization; supports adherence to follow-ups. American Academy of Ophthalmology

12. Antiseptic povidone-iodine (procedure standard)
    Purpose: Infection prevention before intravitreal injection. Mechanism: Broad antimicrobial action on ocular surface. FDA Access Data

13. Analgesics (per visit)
    Purpose: Minor post-injection discomfort relief. Mechanism: Central/peripheral pain modulation; avoid NSAIDs if contraindicated. American Academy of Ophthalmology

14. Topical anesthetics (procedure)
    Purpose: Comfort during injection. Mechanism: Sodium-channel blockade on ocular surface. American Academy of Ophthalmology

15. Antiglaucoma drops pre-/post-injection (select patients)
    Purpose: Manage IOP spikes in high-risk eyes. Mechanism: Aqueous suppression/outflow increase. FDA Access Data

16. Antiplatelet/anticoagulant review (systemic, coordination with PCP)
    Purpose: Balance systemic risks; injections are usually not stopped for these meds. Mechanism: Shared decision-making. American Academy of Ophthalmology

17. Allergy prophylaxis (rare, history-guided)
    Purpose: Manage prior hypersensitivity to drops/tapes. Mechanism: Antihistamines/steroids per clinician. American Academy of Ophthalmology

18. Prophylactic antibiotics are not standard after injections
    Purpose: Avoid resistance, no added benefit shown vs. povidone-iodine alone. Mechanism: Evidence-based procedural hygiene. American Academy of Ophthalmology

19. Treat comorbid eye disease per guidelines (e.g., cataract, dry eye)
    Purpose: Optimize overall vision. Mechanism: Standard eye care pathways. American Academy of Ophthalmology

20. Emergency endophthalmitis protocol
    Purpose: Rapid treatment if severe pain/vision loss after injection. Mechanism: Intravitreal antibiotics per retina service. American Academy of Ophthalmology

Why this matters for BSPD: When CNV complicates BSPD, anti-VEGF (ranibizumab/aflibercept/brolucizumab/faricimab) and, in selected cases, verteporfin PDT are the tools with real-world evidence—mainly case reports/series—showing anatomic and functional gains. Labels guide dosing/safety even when the BSPD indication is off-label. PMC+2journals.publisso.de+2

---

Dietary molecular supplements

There’s no supplement proven to stop BSPD. Guidance below follows macular-health evidence (largely from AMD data) and general eye nutrition. Always discuss with your clinician, especially if pregnant, on anticoagulants, or if you smoke.

1. AREDS2-style antioxidant formula (vit C 500 mg, vit E 400 IU, zinc 80 mg as oxide + copper 2 mg, lutein 10 mg, zeaxanthin 2 mg daily)
   Function/Mechanism: Antioxidant support and macular pigment replacement. In AMD, AREDS2 reduced progression risk vs. older beta-carotene–containing mixes and is safer for former/current smokers (avoid beta-carotene). Role in BSPD is unproven but commonly considered for general macular health. nei.nih.gov+1

2. Lutein (10 mg/day) & 3) Zeaxanthin (2 mg/day)
   Function/Mechanism: Macular pigments filter blue light and may improve contrast sensitivity; evidence strongest in AMD. nei.nih.gov

3. Omega-3 (DHA/EPA) (via diet; supplements show no added AREDS2 benefit)
   Function/Mechanism: Membrane lipids with anti-inflammatory effects; emphasize fish intake over pills. nei.nih.gov

4. Coenzyme Q10
   Function/Mechanism: Mitochondrial cofactor antioxidant; general retinal bioenergetics rationale; clinical benefit in BSPD is unproven. (Use only with clinician approval.) American Academy of Ophthalmology

5. Alpha-lipoic acid
   Function/Mechanism: Redox recycling antioxidant; theoretical retinal support; evidence in BSPD lacking. American Academy of Ophthalmology

6. N-acetylcysteine (NAC)
   Function/Mechanism: Glutathione precursor; reduces oxidative stress; BSPD-specific data absent. American Academy of Ophthalmology

7. Resveratrol
   Function/Mechanism: Polyphenol with antioxidant/anti-angiogenic signals in preclinical studies; clinical retinal data limited. American Academy of Ophthalmology

8. Curcumin
   Function/Mechanism: Anti-inflammatory/antioxidant phytochemical; oral bioavailability issues; role uncertain. American Academy of Ophthalmology

9. Zinc (with copper) (already in AREDS2; avoid extra high dosing without advice)
   Function/Mechanism: Antioxidant enzyme cofactor (e.g., superoxide dismutase); supports RPE; balance with copper to avoid deficiency. nei.nih.gov

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “immunity-boosting” drugs for BSPD, and no approved regenerative or stem-cell drugs for this condition. What exists is research into gene therapy for PRPH2-related disease and cell therapy using stem-cell-derived RPE transplantation for macular diseases. If you see such products marketed for BSPD, be cautious. Participation should only be within regulated clinical trials. PMC+2BioMed Central+2

• Gene therapy (PRPH2 research stage). Mechanism: supply or modify PRPH2 gene to stabilize photoreceptor outer segments. Status: preclinical/early translational; dosing/routes are trial-defined. PMC

• RPE cell transplantation (various platforms). Mechanism: replace/support failing RPE to sustain photoreceptors. Status: early-phase trials in retinal diseases; no BSPD-specific approval. Post-op immunosuppression varies by protocol. BioMed Central+1
  (Four additional “drugs” would be speculative marketing; none are approved for regeneration in BSPD today.)

---

Surgeries/procedures

1. Intravitreal injection procedure (for anti-VEGF drugs)
   Why: Treat CNV quickly to preserve vision. How: Office-based, anesthetic drops, povidone-iodine antisepsis, tiny needle places medicine in the eye; follow-up scans guide intervals. FDA Access Data

2. Photodynamic therapy (PDT) with verteporfin
   Why: Selected CNV patterns not ideal for anti-VEGF alone or adjunctive therapy. How: IV verteporfin + timed laser to close abnormal vessels; strict light avoidance afterward. FDA Access Data

3. Pars plana vitrectomy (PPV) for epiretinal membrane/macular hole (if present)
   Why: Mechanical macular issues causing distortion independent of BSPD. How: Microsurgery removes tractional tissue; not a BSPD cure. American Academy of Ophthalmology

4. Cataract surgery (when lens opacity limits vision)
   Why: Improve optics to maximize remaining macular function; careful counseling on expectations if macula is the limiting factor. How: Phacoemulsification with IOL. American Academy of Ophthalmology

5. Diagnostic imaging procedures (OCT, OCT-A, FA, fundus photography)
   Why: Confirm pattern dystrophy, monitor for CNV. How: Noninvasive imaging (except FA requires IV dye). NCBI

---

Preventions

1. Don’t smoke; avoid secondhand smoke. nei.nih.gov

2. Use UV/blue-filtering sunglasses outdoors; add hats. American Academy of Ophthalmology

3. Keep BP, cholesterol, and blood sugar well controlled. American Academy of Ophthalmology

4. Eat leafy greens and colorful fruits regularly; include fish twice weekly. nei.nih.gov

5. If you’re a current/former smoker, avoid beta-carotene supplements. nei.nih.gov

6. Monitor with an Amsler grid and report changes promptly. en.octclub.org

7. Keep scheduled retina follow-ups and imaging. NCBI

8. Discuss family testing/counseling if PRPH2 or other IRD gene is suspected. American Academy of Ophthalmology

9. After any PDT, strictly avoid bright light as instructed. FDA Access Data

10. Use proper lighting and home safety modifications to prevent falls. American Academy of Ophthalmology

---

When to see a doctor

• Urgently (same day): sudden drop in central vision, new central dark spot, new distortion on Amsler grid, new scotoma, new eye pain/redness after an injection (possible endophthalmitis), flashes/floaters with curtain-like shadow. These may signal CNV or other urgent eye issues. en.octclub.org

• Soon (days–weeks): gradual reading difficulty, increasing waviness, or glare not relieved by lighting changes. American Academy of Ophthalmology

• Routine (as advised): scheduled monitoring visits, imaging checks, and low-vision follow-ups. American Academy of Ophthalmology

---

What to eat & what to avoid

1. Eat leafy greens (spinach, kale) most days. nei.nih.gov

2. Add yellow/orange produce (corn, peppers) for zeaxanthin. nei.nih.gov

3. Eat fish (salmon/sardines/mackerel) twice weekly. nei.nih.gov

4. Choose nuts/legumes/whole grains for overall vascular health. American Academy of Ophthalmology

5. If supplementing, prefer AREDS2-style (no beta-carotene). nei.nih.gov

6. Avoid smoking and secondhand smoke (major retina risk). nei.nih.gov

7. Limit ultra-processed foods high in salt/sugar (vascular health). American Academy of Ophthalmology

8. Moderate alcohol; heavy intake harms general eye health. American Academy of Ophthalmology

9. Avoid excess beta-carotene supplements if you smoke/used to smoke. nei.nih.gov

10. Hydrate and maintain a balanced, colorful plate—food first, supplements as needed. nei.nih.gov

---

FAQs

1. Is BSPD the same as macular degeneration?
   No. It is an inherited pattern dystrophy of the RPE. Some imaging features overlap with AMD, but causes and course differ. NCBI

2. Will I go blind?
   Most people keep usable vision for many years. The main threat is CNV, which is treatable if caught early. ajo.com+1

3. What causes it?
   Often variants in PRPH2 and related genes that affect photoreceptor outer segments and RPE. MedlinePlus

4. Is there a cure?
   No disease-modifying cure yet. Care focuses on monitoring, low-vision rehab, and treating CNV if it occurs. PMC

5. Can vitamins help?
   AREDS2 supplements support macular health in AMD; they’re commonly used but not proven to stop BSPD. Food-first patterns are encouraged. nei.nih.gov

6. If I get CNV, what’s the treatment?
   Office-based anti-VEGF injections (ranibizumab, aflibercept, brolucizumab, faricimab); some cases use verteporfin PDT. FDA Access Data+4FDA Access Data+4FDA Access Data+4

7. How often are injections?
   Labels specify monthly “loading” then extend (every 8–12+ weeks) depending on response and drug. Your retina specialist tailors the plan. FDA Access Data+1

8. Are there risks with injections?
   Yes, but serious events are rare: infection (endophthalmitis), retinal detachment, pressure spikes; common minor ones include redness and floaters. FDA Access Data

9. Is PDT safe?
   It’s an option for certain CNV patterns; you must avoid bright light for ~48 hours after treatment due to photosensitivity. FDA Access Data

10. Should my family get tested?
    Consider genetic counseling to discuss testing and inheritance. American Academy of Ophthalmology

11. Can I drive?
    If legal vision standards are met and you feel safe. Low-vision specialists can advise on filters, mirrors, and training. American Academy of Ophthalmology

12. What changes should I report fast?
    New distortion, central blur, dark spot, or sudden drop in vision—these can indicate CNV. en.octclub.org

13. Are stem-cell treatments available?
    Only in clinical trials; not approved for BSPD. Avoid unregulated clinics. BioMed Central

14. Will cataract surgery help?
    If cataract is limiting vision, yes—expectations depend on macular status. American Academy of Ophthalmology

15. What’s the long-term outlook?
    Often slowly progressive with long stable periods; good monitoring and prompt CNV treatment help protect vision. ajo.com

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 07, 2025.

PDF Documents For This Disease Condition References